ASCO 2026 | Breast cancer updates at ASCO 2026: KEYNOTE-522, SERENA-6, and more

Yeah, I mean, I think it was ASCO with a lot of updates. We saw some Keynote 522 updates in the curative setting with the addition of pembrolizumab to neoadjuvant chemotherapy. I think that was very practice affirming, really showing that we’re benefiting patients with the addition of pembrolizumab in high risk. We also saw the first-line data for giredestrant. We’d already seen a press release that that was negative. We did see a trend in favor of giredestrant. This was not statistically significant, you know, a little bit disappointing. We had already seen Ladera data in the adjuvant setting that was a positive study with giredestrant. So certainly, you know, a proof of principle there for oral SERD in these earlier line settings. We do have other studies coming. Serena 4, for example, is camizestrant. That’s a larger trial. The giredestrant trial was about 900 patients. The Serena 4 trial will be over 1,350 patients. So I’m really hopeful that perhaps we can get a positive result out of the Serena 4 trial. We also saw some updates around PI3 kinase. We saw an update around Serena 6 in terms of progression-free survival 2. We also saw some data around the Trop2 antibody drug conjugates in first line. Again, all of those pretty practice-confirming. We now have Datopotamab deruxtecan approval in first line. So really seeing some of these antibody drug conjugates move up into earlier line of therapy.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.